Format

Send to

Choose Destination
J Gastrointest Cancer. 2015 Jun;46(2):149-55. doi: 10.1007/s12029-015-9702-7.

Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.

Author information

1
Hazelrig Salter Radiation Oncology Center, University of Alabama at Birmingham, 1700 6th Ave S, Birmingham, AL, 35249, USA, ammcdonald@uabmc.edu.

Abstract

PURPOSE:

The purpose of this study was to investigate the effect of radiotherapy on local control and mordibity for patients with resected lymph node-positive pancreatic cancer as compared to gemcitabine-based chemotherapy alone.

MATERIALS AND METHODS:

Sixty-nine patients received adjuvant therapy for pancreatic adenocarcinoma with lymph node involvement after surgical resection and met the inclusion criteria for this analysis. Forty (58 %) patients received postoperative radiotherapy (PORT) to a median dose of 50.4 Gy with capecitabine or 5-fluorouracil concurrently in all but one case; 15 patients also received gemcitabine prior to PORT. Twenty-nine (42 %) patients received gemcitabine-based chemotherapy without PORT for a median of 6 cycles.

RESULTS:

The median overall survival for patients receiving PORT was 24.4 months compared to 25.6 months for patients not receiving PORT (p = 0.943). At 2 years, the rate of local control was 57 % for patients receiving PORT compared to 37 % for those who did not (p = 0.034). At 2 years, the rate of palliative local interventions was 16 % for patients receiving PORT compared to 18 % for patients who did not (p = 0.821).

CONCLUSION:

The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma. The rates of overall survival and palliative interventions did not differ between the two groups.

PMID:
25782589
DOI:
10.1007/s12029-015-9702-7
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center